Which beta-blocker is most suitable for a patient with chronic heart failure with reduced ejection fraction who is taking atorvastatin, omeprazole, ramipril and metformin?

Which beta-blocker is most suitable for a patient with chronic heart failure with reduced ejection fraction who is taking atorvastatin, omeprazole, ramipril and metformin?

• A. Metoprolol
• B. Nebivolol
• C. Carvedilol
• D. Bisoprolol

Answer: (B)

In heart failure with reduced ejection fraction, you want a beta-blocker that is well tolerated, has cardiovascular benefits, and fits with the patient’s other medications and comorbidities. Nebivolol is a highly beta-1 selective blocker that also causes nitric oxide–mediated vasodilation. This combination reduces heart rate and myocardial oxygen demand while lowering afterload, which can help improve HF symptoms and exercise tolerance without adding significant blood pressure or metabolic stress. A key advantage here is its favorable metabolic profile for a patient on metformin, since nebivolol tends to have less negative impact on glucose and lipid metabolism compared with some other beta-blockers. Its drug interaction potential with atorvastatin and omeprazole is minimal, so this patient’s current regimen is unlikely to see meaningful interactions. While other beta-blockers used in HFrEF (like carvedilol, bisoprolol, and metoprolol succinate) have strong evidence in HF, nebivolol’s cardioselectivity, added vasodilatory effect, and good tolerability make it particularly suitable for a patient on multiple agents, including a statin, a PPI, an ACE inhibitor, and metformin.

In heart failure with reduced ejection fraction, you want a beta-blocker that is well tolerated, has cardiovascular benefits, and fits with the patient’s other medications and comorbidities. Nebivolol is a highly beta-1 selective blocker that also causes nitric oxide–mediated vasodilation. This combination reduces heart rate and myocardial oxygen demand while lowering afterload, which can help improve HF symptoms and exercise tolerance without adding significant blood pressure or metabolic stress.

A key advantage here is its favorable metabolic profile for a patient on metformin, since nebivolol tends to have less negative impact on glucose and lipid metabolism compared with some other beta-blockers. Its drug interaction potential with atorvastatin and omeprazole is minimal, so this patient’s current regimen is unlikely to see meaningful interactions.

While other beta-blockers used in HFrEF (like carvedilol, bisoprolol, and metoprolol succinate) have strong evidence in HF, nebivolol’s cardioselectivity, added vasodilatory effect, and good tolerability make it particularly suitable for a patient on multiple agents, including a statin, a PPI, an ACE inhibitor, and metformin.